The rule also extends to medically important biologic products.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
In conjunction with the proposed rule, the FDA has sent Congress a plan for improving the FDA’s ability to react in response to drug shortages.
The FDA will accept comments on the rule until Jan. 3, and comments on the information collection requirements until Dec. 4.
